Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DFP Healthcare Acquisitions Corp. is a blank check company. The Company’s business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying a target business in the healthcare or healthcare-related industries in the United States and other developed countries. The Company focuses its investment effort across the entire healthcare industry, which encompasses services, therapeutics, devices, diagnostics and animal health.The Oncology Institute, Inc. appointed Kimberly (Kim) Tzoumakas to its Board of Directors, effective February 23, 2026, filling a board vacancy by unanimous written consent. The board’s nominating committee determined she meets Nasdaq independence requirements and brings relevant expertise in oncology, pharmacy services and healthcare operations.
Her term runs until the next annual meeting of stockholders, when she is expected to be nominated as part of management’s slate. Under the company’s non-employee director compensation program, she will receive $75,000 per year, paid quarterly, and future restricted stock unit awards. The company also issued a press release, furnished as Exhibit 99.1.
Oncology Institute, Inc. reported that investor Jorey Chernett has filed a Schedule 13G disclosing a significant ownership position in the company’s common stock. Chernett beneficially owns 5,114,944 shares of common stock, representing 5.2% of the class. All of these shares are reported with sole voting and sole dispositive power, with no shared voting or dispositive authority.
The filing indicates this is a passive investment. Chernett certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of Oncology Institute, Inc., and are not held in connection with any transaction intended to have that effect. The date of the ownership event triggering the filing is stated as January 14, 2026.
Oncology Institute, Inc. director Mark Stolper has filed an initial insider ownership report showing no holdings in the company’s stock. In this Form 3, he is identified as a director of Oncology Institute, Inc. (ticker TOI) and indicates that he does not beneficially own any non-derivative or derivative securities of the company as of the event date of 01/02/2026. The report is filed as a single-reporting-person filing and is signed by attorney-in-fact Mark Hueppelsheuser under a power of attorney.
The Oncology Institute, Inc. reported that it has issued a press release reaffirming its 2025 financial guidance and providing a preliminary financial outlook for 2026, along with additional longer-term financial guidance. The press release is included as Exhibit 99.1 to this report and is incorporated by reference.
The company states that the information under Item 2.02, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
The Oncology Institute, Inc. reported that its Board of Directors, by unanimous written consent, appointed Mark D. Stolper to fill a vacancy on the Board effective January 2, 2026. The Board’s Nominating and Corporate Governance Committee determined that he meets Nasdaq’s independence requirements and has the expertise to contribute effectively. He has been appointed to the Audit Committee, will serve as its Chairman, and has been designated the Audit Committee financial expert.
Mr. Stolper’s term runs until the next annual meeting of stockholders, when he is expected to be nominated as part of management’s slate. He will participate in the company’s non-employee director compensation program, receiving $75,000 per year, paid quarterly, plus restricted stock unit awards for his Board service and role as Audit Committee Chairman, to be granted at a later date. The company also issued a press release on January 5, 2026 announcing his appointment.
Oncology Institute, Inc. reported an updated insider transaction for its Chief Financial Officer, who serves as an officer of the company. On 01/02/2026, the CFO disposed of 244 shares of common stock at a price of $3.67 per share in a transaction coded "J." After this sale, the CFO beneficially owned 235,125 shares of common stock directly.
The company explains that the issuer executed this sale to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on January 1, 2026. The filing is marked as an amendment to correct the transaction code, the number of shares sold, and the sale price from an earlier report filed on January 5, 2026.
The Oncology Institute, Inc. chief financial officer reports a small stock sale linked to taxes. On January 2, 2026, the reporting officer sold 247 shares of Oncology Institute common stock at a price of $3.56 per share. After this transaction, the officer beneficially owned 235,122 shares directly.
The filing notes that the proceeds from this sale were used to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on January 1, 2026. This indicates the transaction was tied to compensation-related tax obligations rather than a discretionary reduction in holdings.
Oncology Institute, Inc. director Brad Hively reported selling 13,333 shares of common stock on December 15, 2025. The shares were sold at a volume‑weighted average price of $3.771921 per share, with actual sale prices ranging from $3.770 to $3.785. He used the proceeds to pay tax liabilities that arose from the vesting of a restricted stock unit (RSU) award on November 20, 2025, indicating the transaction was primarily tax-related.
After this sale, Hively beneficially owns 683,721 shares of Oncology Institute common stock, held directly.
TOI has a shareholder planning to sell 13,333 shares of common stock under Rule 144.
The shares were acquired as restricted stock from the issuer on 11/21/2025 and are planned to be sold around 12/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $50,290.74. The issuer had 98,381,340 shares of common stock outstanding.
Oncology Institute, Inc. director Gabriel Ling filed a Form 4 as a single reporting person in connection with Oncology Institute, Inc. common stock. The filing lists Ling’s role as a director of the company and shows an earliest transaction date of 12/01/2025, but the transaction tables in the excerpt do not display any specific share amounts, prices, or derivative positions.